Print

RXi Pharmaceuticals (RXII) Appoints Robert Bitterman and Keith Brownlie to Board of Directors  
6/21/2012 10:24:44 AM

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
//-->